FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

April 30, 2004

CERTIFICATE OF MAILING
37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 30, 2004 — Date
Gina N. Shishima

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/751,606 entitled "OPTIMIZATION OF CANCER TREATMENT WITH IRINOTECAN" – Mark J. Ratain et al.*
Our reference: ARCD:389US
Client reference: UCHI 1014

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A8, B1-B5 and C1-C217.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:389US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104

GNS/kmv
Encl.: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Mark J. Ratain *et al.*

Serial No.: 10/751,606

Filed: January 5, 2004

For: OPTIMIZATION OF CANCER TREATMENT WITH IRINOTECAN

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: ARCD:389US

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

April 30, 2004
Date

Gina N. Shishima

INFORMATION DISCLOSURE STATEMENT

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ARCD:389US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 30, 2004

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,786,344	7/28/98	Ratain *et al.*	514	100	4/17/95
	A2	6,066,645	5/23/00	Hausheer *et al.*	514	283	1/6/99
	A3	6,287,834	9/11/01	Belanger *et al.*	435	193	2/08/99
	A4	6,319,678	11/20/01	Trubetskoy and Shaw	435	15	6/25/99
	A5	6,395,481	5/28/02	Di Rienzo *et al.*	435	6	1/16/99
	A6	6,407,117	6/18/02	Bouscarel *et al.*	514	283	3/23/00
	A7	6,472,157	10/29/02	De Rienzo and Ratain	435	6	2/01/02
	A8	6,479,236	11/12/02	Penny and Galvin	435	6	5/05/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
✓	B1	EP 0919244	6/2/99	Europe			Abstract
✓	B2	WO 00/06776	2/10/00	PCT			
✓	B3	WO 94/22846	10/94	PCT			
✓	B4	WO 95/08986	4/6/95	PCT			
	B5	WO 96/01127	1/18/96	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1 ✓	Abraham *et al.*, "Non-glucocorticoid steriod analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine," *Cancer Chemother. Pharmacol.*, 32(2):116-122, 1993.
	C2 ✓	Akiyama *et al.*, "Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of p-glycoprotein by a vinblastine analog," *Mol. Pharmacol.*, 33(2):144-147, 1988.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C3	Ando *et al.*, "Polymorphisms of UDP-glycuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis," *Cancer Res.*, 60(24):6921-6926, 2000.
	C4	Ansher *et al.*, "Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity," *Hepatology*, 3(6):932-935, 1983.
	C5	Araki *et al.*, "Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11," *Jpn J. Cancer Res.*, 84:697-702, 1993.
	C6	Ariyoshi *et al.*, "Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein," *Jpn. J. Cancer Res.*, 83(5):515-521, 1992.
	C7	Atsumi *et al.*, "Identification of the Metabolites of Irinotecan, a New Derivative of Camptothecin, in Rat Bile and its Biliary Excretion," *Xenobiotica*, 21(9):1159-1169, 1991.
	C8	Barbier *et al.*, "3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 3B7 (UGT2B7)," *Drug Metab. Dispos.*, 28:497-502, 2000.
	C9	Barker *et al.*, "Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy," *J Chromatogr B Biomed Appl*, 681:323-329, 1996.
	C10	Bear, "Drugs transported by-P-glycoprotein inhibit a 40pS outwardly rectifying chloride channel," *Biochem. Biophys. Res. Commun.*, 200(1):513-521, 1994.
	C11	Bell *et al.*, "Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin," *Biochem. Pharmacol.*, 48(3):495-503, 1994.
	C12	Bertrand *et al.*., "Sequential Administration of Camptothecin and Etoposide Circumvents the Antagonistic Cytotoxicity of Simultaneous Drug Administration in Slowly Growing Human Colon Carcinoma HT-29 Cells," *Eur. J. Cancer*, 28A(4-5):743-748, 1992.
	C13	Beutler *et al.*, "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism," *PNAS USA*, 95(14):8170-8174, 1998.
	C14	Bhasker *et al.*, "Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance," *Pharmacogenetics*, 10(8):679-685, 2000.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C15	Bible and Kaufmann, "Cytotoxic synergy between flavopiridol (NSSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration," *Cancer Res.*, 57:3375-3380, 1997.
	C16	Bible and Kaufmann, "Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells," *Cancer Res.*, 56:4856-4861, 1996.
	C17	Bock *et al.*, In: Conjugation reactions in biotransformation, Elsevier, North Holland Biomedical Press, p. 357-364, 1978.
	C18	Boesch and Loor, "Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents," *Anticancer Drugs*, 5(2):229-238, 1994.
	C19	Boesch *et al.*, "Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative," *Exp. Cell. Res.*, 196(1):26-32, 1991.
	C20	Boiteux-Antoine *et al.*, "Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds," *Gen-Pharmacol*, 20(4):407-412, 1989.
	C21	Bosma *et al.*, "Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar Syndrome, Type I," *Hepatology*, 15:941-947, 1992.
	C22	Bosma *et al.*, "The genetic basis of the reduced expression of bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome," *N. Eng. J. Med.*, 333:1171-1175, 1995.
	C23	Burchell and Coughtrie, "UDP-glucuronosyltransferases," *Pharmac. Ther.*, 43:261-289, 1989.
	C24	Burchell *et al.*, "The UDP Glucuronosyltransferase gene suprefamily: suggested nomenclature based on evolutionary divergence, *DNA cell biol.*, 10:487-494, 1991.
	C25	Burger *et al.*, "Pharmacokinetic interaction between rifampin and zidovudine," *Antimicrobial Agents and Chemotherapy*, 37(7):1426-1431, 1993.
	C26	Campain *et al.*, "Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II," *J. Cell Physiol.*, 155(2):414-425, 1993.
	C27	Carlson *et al.*, "Flavopiridol induces G^1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells," *Cancer Res*, 56:2973-2978, 1996.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C28	Carrier *et al.*, "Isolation and characterization of the human UGT2B7 gene," *Biochem and Biophys. Res. Commun.*, 272:616-621, 2000.
	C29	Cascorbi et al., "Frequency of single nucleotide polymorphisms in the p-glycoprotein drug transporter MDR1 gene in white subjects," *Clinc. Pharmacol Ther.*, 69:169-174, 2001.
	C30	Charuk *et al.*, "Interaction of Rat Kidney P-Glycoprotein with a Urinary Component and Various Drugs Including Cyclosporin A," *Am. J. Physiol.*, 266:F66-F75, 1994.
	C31	Chen *et al.*, "Fluorescence polarization in homogeneous nucleic acid analysis," *Genome Res.*, 9:492-498, 1999.
	C32	Chen *et al.*, "Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA," *Biotechniques*, 6:632-638, 1988.
	C33	Cheng *et al.*, "Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7," *Toxicological Sciences*, 45:52-57, 1998.
	C34	Chien *et al.*, "In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer," *Cancer Chemother Pharmaco*, 44:81-87, 1999.
	C35	Chin *et al.*, "Reduced mRNA levels for multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines," *J. Cell Physiol.*, 152(1):87-94, 1992.
	C36	Clarke and Burchell, "The Uridine Diphosphate glucuronosyltransferase multigene family: function and regulation," *Handbook of experimental pharmacology*, 112:3-43, 1994.
	C37	Coffman *et al.*, "Cloning and stable expression of a cDNA encoding a rate liver UDP-Glucuronosyltransferase (UDP_Glucuronosyltransferase 1.1) that catalyzes the glucuronidation of opiods and bilirubin," *Mol. Pharmacol.*, 47:1101-1105, 1995.
	C38	Coffman *et al.*, "Human UGT2B7 catalyzes morphine glucuronidation," *Drug Metab Dispos.*, 25:1-4, 1997.
	C39	Coffman *et al.*, "The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)," *Drug Metab Dispos*, 26:73-77, 1998.
	C40	Cordon-Cardo *et al.*, "Expression of the multidrug resistant gene product (P-glycoprotein) in human normal and tumor tissues," *J. Histochem. Cytochem.*, 38:1277-1287, 1990.
	C41	Czech *et al.*, "Antitumoral activity of flavone L86-8275," *Int J Oncol*, 6:31-66, 1995.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C42	Davies and Schnell, "Oltipraz-induced amelioration of acetaminophen hepatotoxicity in hamseters," *Toxicology and Applied Pharmacology*, 109:29-40, 1991.
	C43	de Forni *et al.*, "Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients," *Cancer Res.*, 54:4347-4354, 1994.
	C44	De Lannoy *et al.*, "Cyclosporin and Quinidine Inhibition of Renal Digoxin Excretion: Evidence for Luminal Secretion of Digoxin," *Am. J. Physiol*, 263:F613-F622, 1992.
	C45	De Morais *et al.*, "Biotransformation and Toxicity of Acetaminophen in Congenic RHA Rats with or without a Hereditary Deficiency in Bilirubin UDP-Glucuronosyltransferase," *Toxicology and Applied Pharmacology*, 117:81-87, 1992.
	C46	Decleves et al., "A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encloding the P-glycoprotein," *Human Mutation,* 15: 486, 2000.
	C47	Dhainaut *et al.*, "New Triazine Derivatives as Potent Modulators of Multidrug Resistance," *J. Med. Chem.*, 35:2481-2496, 1992.
	C48	Di Carlo *et al.*, "Flavonoids: old and new aspects of a class of natural therapeutic drugs," *Life Sci*, 65:337-353, 1999.
	C49	Di Rienzo *et al.*, "Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene", *American Society for Clinical Pharmacology and Therapeutics*, Ninety Ninth Annual Meeting, New Orleans, Abstract OII-B-3, page 207, 1998.
	C50	Diasio et al., "Clinical pharmacology of 5-fluorouracil," *Clin Pharmacokinet,* 16:215-237, 1989.
	C51	Dobbs and Twelves, "What is the effect of adjusting epirubicin doses for body surface area?" *British Journal of Cancer,* 78(5):662-666, 1998.
	C52	Doige *et al.*, "ATPase activity of partially purified P-glycoprotein from multidrug-resistant chinese hamster ovary cells," *Biochim. Biophys. Acta.*, 1109(2):149-160, 1992.
	C53	Drees *et al.*, "Flavopiridol (86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells," *Clin Cancer Res*, 3:273-279, 1997.
	C54	Egner *et al.*, "Regulation of Phase 2 Enzyme Induction by Oltipraz and other Dithiolethiones," *Carcinogenesis*, 15(2):177-181, 1994.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain *et al.*	
(Use several sheets if necessary)	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	Ewesuedo and Ratain, "Topoisomerase I inhibitors," *Oncologist*, 2(6):359-364, 1997.
	C56	Evans and Relling, "Automated high-performance liquid chromatographic assay for the determinationof 7-ethoxycoumarin and umbelliferone," *J. Chromatogr.*, 578:141-145, 1992.
	C57	Ford *et al.*, "Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines," *Cancer Res.*, 50(6):1748-1756, 1990.
	C58	Fournel *et al.*, "Structure-dependent induction of bilirubin glucuronidation and lauric acid 12-hydroxylation by arylcarboxylic acids chemically related to clofibrate," *Biochimica at Biophysica Acta*, 842:202-213, 1985.
	C59	Foxwell *et al.*, "Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein," *Mol. Pharmacol.*, 36:543-546, 1989.
	C60	Friche *et. al.*, "In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues" *Biochem. Pharmacol.*, 39:1721-1726, 1990.
	C61	GenBank Accession Number AF297093.
	C62	GenBank Accession Number NM_001074.
	C63	Gestl *et al.*, "Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in Situ breast cancers," *American Journal of Pathology*, 160(4):1467-1479, 2002.
	C64	Gram *et al.*, "Clinical relevance of gentic polymorphisms in drug oxidation," *Clinical Relevance of Genetic Polymorphisms in Drug Oxidation*, 1992.
	C65	Green *et al.*, "Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides," *Drug Metab. Dispos.*, 23:299-302, 1995.
	C66	Gruol *et al.*, "Reversal of multidrug resistance by RU 486[1]" *Cancer Res.*, 54(12):3088-3091, 1994.
	C67	Guillamette *et al.*, "Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans," *Cancer Res.*, 60:950-956, 2000.
	C68	Gunn, "Hereditary Acholuric Jaundice," *J. Hered.*, 29:137-139, 1938.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C69	Gupta *et al.*, "Metabolic Fate of Irinotecan in humans: Correlation of Glucuronidation with Diarrhea," *Cancer Res.*, 54:3723-3725, 1994.
	C70	Gupta *et al.*, "Pharmacokinetic and pharmacodynamic evaluation of the topisomerase inhibitor Irinotecan in cancer patients," *J. Clin. Oncol.*, 15:1502-1510, 1997.
	C71	Gupta *et al.*, "Modulation of glucoronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital, *Cancer Chemother. Pharmacol.*, 39(5):440-444, 1997.
	C72	Gupta *et al.*, "Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A., *Cancer Res.*, 56(6):1309-1314, 1996.
	C73	Gupta *et al.*, "Role of carboxyl esterase in the metabolism of CPT-11, a camptothecin analog, in humans" *Pharm. Res.*, 11:S450, 1994.
	C74	Gutmann *et al.*, "Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro," *Drug Metab Dispos.* 27:937-941, 1999.
	C75	Hait *et al.*, "Terferadine (seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells" *Biochem. Pharmacol.*, 45(2):401-406, 1993.
	C76	Hamada *et al.*, "Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein" *Cancer Res.*, 50(11):3167-3171, 1990.
	C77	Harding *et al.*, "Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells," *PNAS, USA*, 85:8381-8385, 1988.
	C78	Hecht *et al.*, "4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, metabolites of a tobacco-specific lung carcinogen, in the urine of black and white smokers," *Proceedings of the American Association for Cancer Research*, 35:1702, 1994.
	C79	Hendricks *et al.*, "Effect of P-Glycoprotein Expression on the Accumulation and Cytotoxicity of Topotecan (SK&F 104864), a New Campotthecin Analogue," *Cancer Research*, 52:2268-2278, April 1992.
	C80	Hjelle, "Hepatic UDP-Glucuronic Acid Regulation during Acetaminophen Biotransformation in Rats," *The Journal of Pharmacology and Experimental Therapeutics*, 237(3):750-756, 1986.
	C81	Hoffmeyer *et al.*, "Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations an dcorrelation of one allele with p-glycoprotein expression and activity in vivo," *PNAS*, 28:97(7):3473-3478, 2000.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C82	Holthe *et al.*, "Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1a1*28 polymorphisms in cancer patients on chronic morphine therapy," *European Journal of Clinical Pharmacology,* 58: 353-356, 2002.
	C83	Hooijberg *et al.*, "Potent interaction of flavopiridol with MRP1," *British J. of Cancer,* 81:269-276, 1999.
	C84	Hsu *et al.*, "Universal SNP genotyping assay with fluorescence polarization detection," *BioTechniques*, 31:560-570, 2001.
	C85	Hunter *et al*, "Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial caco-2 cell layers" *Pharm. Res.*, 10(5):743-749, 1993.
	C86	Ichikawa-Haraguchi *et al.*, "Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland" *Biochim. Biophys. Acta*, 1158(3):201-208, 1993.
	C87	Innocenti *et al.*, "Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan," *Drug Metab. Dispos.*, 29(4 pt 2):596-600, 2001.
	C88	Innocenti *et al.*, "Pharmacogenetics: a tool for individualizing antineoplastic therapy," *Clin. Pharmacokinet.*, 39(5):315-325, 2000.
	C89	Innocenti *et al.*, "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyl transferase 2B7," *Drug Metab. Dispos.*, 29(5):686-692, 2001.
	C90	Innocenti *et al.*, "Epirubicin is glucuronidated by UGT2B7," *Clinical Pharmacology and Therapeutics*, 67(2):100, Abstract PI-44, 2000.
	C91	Innocenti et al., "Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea," *Clinical Cancer Research,* 6:3400-3405, 2000.
	C92	Innocenti *et al.*, "Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups," *Pharmacogenetics J.*, 12(9):725-733, 2002.
	C93	Inoue *et al.*, "Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase" *J. Biol. Chem.*, 268(8):5894-5898, 1993.
	C94	Ishii *et al.*, "Octamer transcription factor-1 enhances hepatic nuclear factor-1 α-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter," *Molecular Pharmacology*, 57:940-947, 2000.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C95	Ito et al., "Polymorphism of the abc transporter genes mdr1, mrp1 and mrp2/cmoat, in healthy japanese subjects," *Pharmacogenetics,* 11:175-184, 2001.
	C96	Iyer and Ratain, "Pharmacogenetics and cancer chemotherapy," *Eur J Cancer*, 34:1493-1499, 1998.
	C97	Iyer *et al.*, "Genetic basis for the glucuronidation of SN-38: Role of UGT*1 isoform," *Clinical Pharmacology and Therapeutics*, 61:Abstract, 1997.
	C98	Iyer *et al.*, "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucoronosyltransferase isoform 1A1 in the glucouronidation of its active metabolite (SN-38) in human liver microsomes," *J. Clin. Invest.*, 101(4):847-854, 1998.
	C99	Iyer *et al.*, "Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1a1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome," *Ann Oncol* 9(Supplement 2):61, abstract #230, 1998.
	C100	Iyer *et al.*, "UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan," *Program Proceedings of the American Society of Clinical Oncology*, 16:Abstract, 1997.
	C101	Iyer *et al.*, "Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan and bilirubin glucoronidation in human liver tissue with UGT1A1 promoter polymorphism," *Clin. Phamacol. Ther.*, 65(5):576-582, 1999.
	C102	Iyer, "Inherited variations in drug-metabolizing enzymes: significance in clinical oncology," *Mol Diagnosis,* 4:327-333, 1999.
	C103	Iyer *et al.*, "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity," *Pharmacogenetics J.*, 2(1):43-47, 2002.
	C104	Iyer *et al.*, "Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice," *Cancer Chemother. Pharmacol.*, 49(4):336-341, 2002.
	C105	Jager *et al.*, "Metabolism of the anticancer drug vlavopiridol, a new inhibitor of cyclin dependent kinases in rat liver," *Life Sci.,* 62:1861-1873, 1998.
	C106	Jin *et al.*, "cDNA cloning and expression of two new members of the human glucuronosyltransferase 2B subfamily," *Biochem. Biphys. Res. Comm.*, 194(1):496-503, 1993.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C107	Jin *et al.*, "Complementary deoxyribonucleic acid cloning and expression of human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs," *J. Pharm. Experim. Therap.*, 264(1):475-479, 1993.
	C108	Kamimoto *et al.*, "The function of GP-170, the multidrug resistant gene product, in rat liver canalicular membrane vesicles," *J. Biol. Chem.*, 264:11693-11698, 1989.
	C109	Kamiwatari *et al.*, "Correlation between reversing of multidrug resistance and inhibiting of [^{3}H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydrophyridine analogues in a human cell line," *Cancer Res.*, 49(12):3190-3195, 1989.
	C110	Kaneda *et al.*, "Metabolism and Pharmacokinetics of the campothecin analogue CPT-11 in the mouse," *Cancer Res.*, 50:1715-1720, 1990.
	C111	Kano *et al.*, "Effects of CPT-11 in Combination with Other Anti-Cancer Agents in Culture," *Int. J. Cancer*, 50(4):604-610, 1992.
	C112	Karato *et al.*, "Phase I Study of CPT-11 and Etoposide in Patients with Refractory Solid Tumors," *J. Clin. Oncol.*, 11(10):2030-2035, 1993.
	C113	Kaufmann, "Antagonism Between Camptothecin and Topoisomerase II-Directed Chemotherapeutic Agents in a Human Leukemia Cell Line," *Cancer Res.*, 51(4):1129-1136, 1991.
	C114	Kaur *et al.*, "Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275," *J Natl Cancer Inst.*, 84:1736-1740, 1992.
	C115	King *et al.*, "The Glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-Glucuronosyltransferase 1.1," *Arch. Biochem. Biophys.*, 332:92-100, 1996.
	C116	Kiue *et al.*, "Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents," *Cancer Res.*, 50(2):310-317, 1990.
	C117	Klein *et al.*, "An inventory of the human ABC proteins," *Bioch Biophys Acta,* 1461:237-262, 1999.
	C118	Klein *et al.*, "Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucoronide," *Clin. Pharmacol. Ther.*, 72(6):638-647, 2002.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	**Applicant** Mark J. Ratain *et al.*	
(Use several sheets if necessary)	**Filing Date:** January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C119	Kusuhara *et al.*, "Reduced folate derivatives are endogenous substrates for cmoat in rats," *Am J Physiol.*, 275(4 Pt 1):G789-G796, 1998.
	C120	Lampe *et al.*, "Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)," *Cancer Epidemiology, Biomarkers and Prevention, american Association for Cancer Research,* 9:329-333, 2000.
	C121	Lennard *et al.*, "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism," *Clin. Pharmacol. Ther.*, 46:149-154, 1989.
	C122	Lennard, "The clinical pharmacology of 6-mercaptopurine," *Eur J Clin Pharmacol*, 43:329-339, 1992.
	C123	Levesque *et al.*, "Characterization and substrate specificity of UGT2B4 (E^{458}: a udp-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics,* 9:207-216, 1999.
	C124	Levesque *et al.*, "Isolation and characterization of UGT2B15(Y^{85}): a UDP-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics*, 7:317-325, 1997.
	C125	Lokeic *et al.*, "Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine," *Cancer Chemother. Pharmacol.*, 36:79-82, 1995.
	C126	Lomri *et al.*, "Hepatocellular transport: role of atp-binding cassette proteins," *Semin. Liv. Dis.*, 16: 201-210, 1996.
	C127	Losiewicz *et al.*, "Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275," *Biochem Biophys Res Commun,* 201:589-595, 1994.
	C128	Lubet *et al.*, "A Pleiotropic Response to Phenobarbital-Type Enzyme Inducers in the F344/NCr RAT," *Chemical Pharmacology*, 43(5):1067-1078, 1992.
	C129	Lum *et al.*, "Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance," *J. Clin. Oncol.*, 10:1635-1642, 1992.
	C130	Mackenzie *et al.*, "Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance," *Clin. Chem. Lab. Med.*, 38(9):889-892, 2000.
	C131	Mackenzie *et al.*, "The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence," *Pharmacogenetics,* 7:255-269, 1997.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C132	Magdalou *et al.*, "Peroxisome proliferators as inducers and substrates of UDP-glucuronosyltransferases," *Biol. Cell.*, 77(1):13-16, 1993.
	C133	Makhija *et al.*, "Cytotoxicity of flavopiridol in ovarian cancer cells alone and in combination with CDDP," *Gynecoligic Oncology*, 68(1):83, Abstract #43, 1998.
	C134	Mani and Ratain, "Promising new agents in oncologic treatment," *Curr. Opin. Oncol.*, 8(6):525-534, 1996.
	C135	Manning and Franklin, "Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by L-buthionine-S,R-sulfoximine without induction of cytochrome P-450," *Toxicology*, 65:149-159, 1990.
	C136	Mazzanti *et al.*, "Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles," *Hepatology*, 20(1 Pt 1):170-176, 1994.
	C137	McKinney and Hosford, "ATP-stimulated tetraethylammonium transport by rabbit renal brush border membrane vesicles," *J. Biol. Chem.*, 268(10):6886-6895, 1993.
	C138	Mechetner and Roninson, "Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody," *Proc. Natl. Acad. Sci. USA*, 89(13):5824-5828, 1992.
	C139	Meech and Mackenzie, "Determinants of udp glucuronosyltransferase membrane association and residency in the endoplasmic reticulum," *Arch Biochem Biophys.*, 356:77-85, 1998.
	C140	Michelson and Slate, "A Mathematical Model for the Inhibition of the Multidrug Resistance-Associated P-Glycoprotein Pump," *Bulletin of Mathematical Biology*, 56(2):207-223, 1994.
	C141	Mick *et al.*, "Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of bilary index and intestinal toxicity," *J. Clin. Oncol.*, 14(7):2012-2019, 1996.
	C142	Miki and Kotake, "Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts," *Hinyokika Kiyo*, 39(12):1221-1225, 1993.
	C143	Miller *et al.*, "P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil," *J. Clin. Oncol.*, 9(1):17-24, 1991.
	C144	Miners and Mackenzie, "Drug glucuronidation in humans," *Pharmacol Ther.*, 51:347-369, 1991.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C145	Miyamoto *et al*, "Multidrug resistance in yoshida rat ascites hepatoma cell lines" *Anticancer Res.*, 12(3):649-653, 1992.
	C146	Miyamoto *et al.*, "Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo," *Cancer Res.*, 53(7):1555-1559, 1993.
	C147	Miyamoto *et al.*, "Reversal of vinblastine resistance by a new staurosporine derivate, NA-382, in P388/ADR cells" *Cancer Lett.*, 64(2):177-183, 1992a.
	C148	Monaghan *et al.*, "Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome," *Lancet*, 347:578-581, 1996.
	C149	Morris *et al.*, "Interaction of forskolin with the P-glycoprotein multidrug transporter," *Biochemistry*, 30(34):8371-8379, 1991.
	C150	Muller *et al.*, "ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein," *FEBS Lett.*, 343(2):168-172, 1994.
	C151	Murthi *et al.*, "Structure-activity relationship studies of flavopiridol analogues," *Bioorganic Med Chem Ltrs*, 10:1037-1041, 2000.
	C152	Nakajima *et al.*, "Involvement of multiple UDP-glucoronosyltransferase 1A isoforms in glucoronidation of 5-(4'-hydroxyphenyl-)-5-phenylhydantoin in human liver microsomes," Drug Metabolism and Disposition, 30(11):1250-1256, 2002.
	C153	Narita *et al.*, "Inhibition of Beta-Glucuronidase by Natural Glucuronides of Kampo Medicines Using Glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a Substrate," *Xenobiotica*, 23(1):5-10, 1993.
	C154	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?" *Clin Gen*, 56:247-258, 1999.
	C155	Negoro *et al.*, "Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer," *Journal of the National Cancer Institute*, 83(16):1164-1168, 1991.
	C156	Niwa *et al.*, "Effect of a dihydropridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2,-dioxaphosphorinan-2-y1)-1-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-(pyridinecarboxylate on reversing in vivo resistance of tumor cells to adrianmycin[1]," *Cancer Res.*, 52(13):3655-3660, 1992.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C157	Ohe *et al.*, "Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion," *Journal of the National Cancer Institute,* 84(12):972-974, 1992.
	C158	Ohi *et al.*, "Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study," *Cancer Chemother Pharmacol*, 30:S50-S54, 1992.
	C159	Okamura *et al.*, "Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney," *J. Pharmacol. Exp. Therap.*, 266:1614-1619, 1993.
	C160	Owens and Ritter, "Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity and regulation," *Progress in Nucleic Acid Research and Molecular Biology*, 51:305-338, 1995.
	C161	Perdu and Germain, "Identification of novel polymorphisms in the pm5 and mrp1(abcc1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum," *Human Mutation,* 17:74-75, 2001.
	C162	Perez *et al.*, "Mechanisms and Modulation of Resistance to Chemotherapy in Ovarian Cancer," *Cancer Supplement*, 71(4):1571-1580, February 1993.
	C163	Pourtier-Manzanedo *et al.*, "Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin a –responding mouse spleen cells by P-glycoprotein blockers," *Oncol. Res.*, 4:473-480, 1992.
	C164	Prochaska and Fernandes, "Elevation of serum Phase II enzymes by anticarcinogenic enzyme inducers: markers for a chemoprotected state?," *Carcinogenesis*, 14(12):2441-2445, 1993.
	C165	Purba *et al.*, "The metabolism of 17 α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites," *Br. J. Clin. Pharmacol.*, 23:447-453, 1987.
	C166	Radominska-Pandya *et al.*, "Human UDP-glucuronosyltransferase 2B7," *Curr. Drug. Metab.*, 2:283-298, 2001.
	C167	Rajaonarison *et. al.*, "In vitro glucuronidation of 3'-azido-3' –deoxythymidine by human liver," *Drug Metab. Disp.*, 19:809-815, 1993.
	C168	Ramirez *et al.*, "In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes," *Pharm. Res.*, 19(5):588-594, 2002.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant** Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	**Group:** 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C169	Ramírez *et al.*,. "In vitro glucuronidation of flavopridol (NSC649890) (flavo) by human liver microsomes," *Clin Pharmacol Ther*, 63:149, Abstract # PI-50, 1998.
	C170	Ratain et al., "Paradoxical relationship between acetylator phenotype and amonafide toxicity," *Clin. Pharmacol. Ther.*, 50:573-579, 1991.
	C171	Ratain, "Irinotecan dosing: does the CPT in CPT-11 stand for "Can't predict toxicity?'" *J. Clin. Oncol.*, 20(1):7-8, 2002.
	C172	Ratain, "Insights into the pharmacokinetics and pharmacodynamics of irinotecan," *Clin. Cancer Res.*, 6:3393-3394, 2000.
	C173	Ritter *et al.*, "A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini," *J. Biol. Chem.*, 267:3257-3261, 1992.
	C174	Ritter *et al.*, "Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells," *J. Biol. Chem.*, 226:1043-1047, 1991.
	C175	Robert, "Clinical pharmacokinetics of epirubicin," *Clin. Pharmacokinet,* 26:428-438, 1994
	C176	Robey et al., "Overexpression of the atp-binding cassette half-transporter, abcg2 (mxr/bcrp/abcp1), in flavopiridol-resistnat human breast cancer cells," *Clinical Cancer Res.*, 7:145-152, 2001.
	C177	Rothenberg *et al.*, "Phase I and Pharmacokinetic Trial of Weekly CPT-11," *Journal of Clinical Oncology*, 11(11):2194-2204, 1993.
	C178	Rowinsky *et al.*, "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks," *Cancer Research*, 54:427-436, 1994.
	C179	Rowinsky *et al.*, "Taxol: Pharmacology, Metabolism and Clinical Implications," *Cancer Surv.*, 17:283-304, 1993.
	C180	Rund et al, "A mutation in the promoter of the multidrug resistance gene (mdr1) in human hematological malignancies may contribute to the patogenesis of resistant disease," *Adv. Exp Med Biol.*, 457:71-75, 1999.
	C181	Saeki *et al.*, "Human P-Glycoprotein Transports Cyclosporin A and FK506," *The Journal of Biological Chemistry*, 268(9):6077-6080, 1993.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain *et al.*	
(Use several sheets if necessary)	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C182	Sakata *et al.*, "Preventive Effect of TJ-14, a Kampo (Chinese herb) Medicine, on Diarrhea Induced by Irinotecan Hydrochloride (CPT-11)," *Gan-To-Kagaku-Ryoho*, 21(8):1241-4, July 1994; Abstract only.
	C183	Samuels *et al.*, "Modulation of vinblastine resistance with cyclosporine: A phase I study," *Clin. Pharmacol. Ther.*, 54:421-429, 1993.
	C184	Sausville et al., "Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target," *Pharmacol Ther.*, 82:285-292, 1999.
	C185	Schinkel *et al.*, "Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," *Cell*, 77(4):491-502, 1994.
	C186	Schrenk *et al.*, "Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates," *Hepatol.*, 17:854-860, 1993.
	C187	Schrump et al., "Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells," *Clin Cancer Res.*, 4:2885-2890, 1998.
	C188	Senderowicz et al., "Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms," *J Clin Oncol.*, 16:2986-2999, 1998.
	C189	Shapiro et al., "Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines," *Clin. Cancer Res.*, 5:2925-2938, 1999.
	C190	Sherr, "Cancer cell cycles," *Science,* 274:1672-1677, 1996.
	C191	Shirai *et al.*, "Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein," *Biochim. Biophys. Acta*, 1222(3):400-404, 1994.
	C192	Sinicrope *et al.*, "Modulation of P-glycoprotein-mediated transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles," *J. Biol. Chem.*, 267:24995-25002, 1992.
	C193	Slichenmyer *et al.*, "Camptothecin Analogues: Studies from The Johns Hopkins Oncology Center," *Cancer Chemother. Pharmacol.*, 34:S53-S57, 1994.
	C194	Slichenmyer *et al.*, "The Current Status of Camptothecin Analogues as Antitumor Agents," *Journal of the National Cancer Institute*, 85(4):271-291, February 1993.
	C195	Stadler et al., "Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a university of chicago phase II consortium study," *J Clin Oncol.*, 18:371-375, 2000.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain *et al.*	
(Use several sheets if necessary)	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C196	Stinson *et al.*, "Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection," *Cancer Chemother. Pharmacol.*, 42(4):261-265, 1998.
	C197	Stocker, "Bilirubin is an antioxidant of possible physiological importance," *Science*, 235:1043-1046, 1987.
	C198	Strassburg *et al.*, "Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7," *J. Hepat.*, 34(6):865-872, 2001
	C199	Sugatani *et al.*, "Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia," *Biochem. Biophys. Res. Commun.*, 292(2):492-497, 2002.
	C200	Sugatani *et al.*, "The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR," *Hepatology*, 33(5):1232-1238, 2001.
	C201	Suzuki, "Antitumor drugs and potentiators aiming circumvention of drug resistance," *Jpn J Cancer Chemother*, 17:335-341, 1990.
	C202	Tamai and Safa, "Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells," *J. Biol. Chem.*, 265:16509-16513, 1990.
	C203	Taudou *et al.*, "Inhibition of DNA Synthesis and DNA Fragmentation in Stimulated Splenocytes by the Concerted Action of Topoisomerase I and II Poisons," *Biochem. Pharmacol.*, 45(2):331-337, 1993.
	C204	Thalhammer *et al.*, "Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport," *Eur. J. Pharmacol.*, 270(2-3):213-220, 1994.
	C205	Thomas *et al.*, "Phase I clincial and pharmacokineti trial of flavopiridol," *Proc Am Assoc Cancer Res*, 38:1496, Abstract #1496, 1997.
	C206	Toide *et al.*, "Hepatocyte nuclear factor 1α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in humna livers," *Drug Metabolism and Disposition*, 30(6):613-615, 2002.
	C207	Trump *et al.*, "High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine," *J. Natl. Cancer Inst.*, 84(23):1811-1816, 1992.

25389367.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain *et al.*	
(Use several sheets if necessary)	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C208	Tsuruo *et al.*, "Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors *in vitro* and *in vivo*," *Cancer Chemother. Pharmacol.*, 21:71-74, 1988.
	C209	Tucker, "Clinical implications of genetic polymorphism in drug metabolism," *J. Pharm. Pharmacology*, 46:417-424, 1994.,
	C210	Vezmar and Georges, "Reversal of mrp-mediated doxorubicin resistance with quinoline-based drugs," *Biochem Pharmacol.*, 59:1245-1252, 2000.
	C211	Vore, "Canalicular transport: Discovery of ATP-dependent mechanisms," *Toxicol. Appl. Pharmacol.*, 118:2-7, 1993.
	C212	Wade *et al.*, "Variability in the pharmacokinetics of epirubucin: a population analysis," *Cancer Chemother. Pharmacol.*, 29:391-395, 1992.
	C213	Watanabe *et al.*, "Kinetic Analysis of Hepatobiliary Transport of Vincristine in Perfused," *Journal of Hepatology*, 16:77-88, 1992.
	C214	Wilson *et al.*, "A relationship between multidrug resistance and growth-state dependent cytotoxicity of the lysosomotropic detergent N-dodecylimidazole," *Biochem. Biophys. Res. Commun.*, 176(3):1377-1382, 1991.
	C215	Worland *et al.*, "Alteration of the phosphorylation state of $p34^{cdc2}$ kinase by the flavone L86-8275 in breast carcinoma cells," *Biochem Pharmacol*, 46:1831-1840, 1993.
	C216	Zacherl *et al.*, "Inhibition of P-Glycoprotein-Mediated Vinblastine Transport Across HCT-8 Intestinal Carcinoma Monolayers by Verapamil, Cyclosporine A and SDZ PSC 833 in Dependence on Extracellular pH," *Cancer Chemother. Pharmcol.*, 34:125-132, 1994.
	C217	Zhang *et al.*, "Inhibitory Effects of Homoharringtonine and Hydroxycamptothecin in Combination with Other Agents on Cancer Cell Growth," *Asia Pac. J. Pharmacol.*, 7:191-195, 1992.

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.